| Description: |
SYP-5 is a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. |
| Target: |
HIF[1] |
| In Vitro: |
SYP-5 inhibits hypoxia-induced upregulation of HIF-1. SYP-5 inhibits HIF-1 and downstream gene expression in Hep3B and Bcap37 cells. SYP-5 inhibits tumor cell migration and invasion, as well as tumor angiogenesis, which are mediated by suppressing PI3K/AKT- and MAPK/ERK-dependent HIF-1 pathway. The proteins of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMP)-2 that are targets of HIF-1, are down-regulated by SYP-5. SYP-5 displays significant inhibition on hypoxia-induced overexpression of VEGF and MMP2 in both cell lines. In the tube formation assay, SYP-5 suppresses angiogenesis induced by hypoxia and VEGF in vitro. SYP-5 also retards the Hep3B and Bcap37 cells migration and invasion induced by hypoxia and FBS. SYP-5 specifically inhibits hypoxic induction of luciferase expression in U251-HRE but not in U251-pGL3[1]. |
| Cell Assay: |
The cells (1×105 cells/mL) are seeded into 96-well culture plates. After overnight ncubation, the cells are treated with various concentrations of SYP-5 (2, 10, 50 μM) for 24 h. Then 10μLMTT) solution (2.5 mg/mL in PBS) is added to each well, and the plates are incubated for additional 4 h at 37°C. After centrifugation (2500 rpm, 10 min), the medium containing MTT is aspirated, and 100 μL DMSO is added. The optical density of each well is measured at 570 nm with a SpectraMax Paradigm Reader[1]. |
| References: |
[1]. Wang LH, et al. SYP-5, a novel HIF-1 inhibitor, suppresses tumor cells invasion and angiogenesis. Eur J Pharmacol. 2016 Nov 15;791:560-568. |
